10 registrations that name propolis as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 10 registrations
Status
Phase
All 10 registrations
RecruitingNCT06288204
Green Propolis Extract and Royal Jelly in Hypertensive Patients and/or With Chronic Kidney Disease
No phase
Universidade Federal Fluminense
About 153 people
Started Oct 1, 2024
In plain words A study of propolis in people 18 to 75, run by Universidade Federal Fluminense. It plans to enroll about 153 people at 2 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: Chronic Kidney Diseases; Hypertension; Cardiovascular Diseases.
patients in stages 3 and 5 of CKD (GFR from 15 to 59 mL/min),
patients receiving ambulatorial nutrition treatment at least 6 months
patients on regular Hemodialysis treatment for at least 6 months
patients using one to three antihypertensive drugs
The exclusion criteria are on the listing.
What it tests, as registered
Propolis associated with Royal Jelly; Royal Jelly; Placebo
Registered summary
This work aims to evaluate the effects of the association of green propolis extract with royal jelly on inflammation and oxidative stress in participants with chronic kidney diseases (CKD) and Systemic arterial hypertension (SAH), in a longitudinal, randomized, double-blind, placebo-controlled clinical trial that will be carried out for 2 months.
Where, as registered
No US site; Brazil (2).
RecruitingNCT06903546
The Effect of Propolis Administration on Cholesterol Level in Diabetic Type 2 Patients
Phase 4
Universitas Indonesia
About 64 people
Started Mar 18, 2025
In plain words A Phase 4 study of propolis in people 35 to 59, run by Universitas Indonesia. It plans to enroll about 64 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 35 to 59. Conditions: Diabetes Mellitus Type 2.
Controlled Diabetes Mellitus type 2 with HbA1c <7.5%
BMI 23-35 kg/m2
On anti-cholesterol therapy
The exclusion criteria are on the listing.
What it tests, as registered
Propolis drops; Placebo
Registered summary
The goal of this clinical trial is to learn if propolis administration works to change the level of Low Density Lipoprotein (LDL) and High Density Lipoprotein cholesterol (HDL) in diabetic type 2 patients. The main questions it aims to answer are: \- Is giving 1 drops/ 10kg/ times, twice daily for 8 weeks will change the level of LDL and HDL level in diabetic type 2 patients compared to placebo? Researchers will compare propolis to a placebo (a look-alike substance that contains no drug) to see if propolis works to change LDL and HDL cholesterol level. The full summary is on the listing.
Where, as registered
No US site; Indonesia (1).
RecruitingNCT07692438
Taiwan Green Propolis for Blood Lipids and Body Fat in Patients With MASLD
No phase
Taipei Medical University
About 60 people
Started May 28, 2025
In plain words A study of propolis in people 18 to 80, run by Taipei Medical University. It plans to enroll about 60 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 80. Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease; Non-alcoholic Fatty Liver Disease NAFLD; Dyslipidemia; Obesity & Overweight.
Adults aged 18 to 80 years
Diagnosis of hepatic steatosis (fatty liver) confirmed by abdominal ultrasound, PLUS at least one of the following metabolic risk factors:
Overweight or obesity: BMI >= 23 kg/m\^2
Elevated waist circumference: >= 90 cm in men or >= 80 cm in women (South Asian and Chinese criteria)
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Taiwan green propolis capsule; Placebo capsule
Registered summary
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common chronic liver condition linked to excess body fat, high blood lipids, and other metabolic problems. Taiwan green propolis is a natural health product collected by bees from plants, which has shown potential benefits for blood lipids and body fat in laboratory and animal studies. However, its effects in people with MASLD have not been well established in clinical trials. This study is a double-blind, randomized, placebo-controlled trial enrolling up to 60 adults with MASLD at Dalin Tzu Chi Hospital in Taiwan. The full summary is on the listing.
Where, as registered
No US site; Taiwan (1).
RecruitingNCT07596966
EFFECTS OF PROPOLIS AND ROYAL JELLY SUPPLEMENTATION ON INFLAMMATORY AND OXIDATIVE STRESS MARKERS IN PATIENTS WITH SYSTEMIC ARTERIAL HYPERTENSION
No phase
Universidade Federal Fluminense
About 48 people
Started Oct 15, 2025
In plain words A study of propolis in people 18 to 75, run by Universidade Federal Fluminense. It plans to enroll about 48 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: Systemic Arterial Hypertension; Inflammation.
Diagnosis of stage 1 and 2 hypertension
Regular treatment for more than 6 months
There have been no changes in medication doses over the last three months.
The exclusion criteria are on the listing.
What it tests, as registered
Placebo; Royal Jelly + Propolis Group
Registered summary
The study aims to evaluate the effect of the royal jelly and propolis on inflammation and oxidative stress in participants with systemic arterial hypertension. A longitudinal double-blind randomized clinical trial will be carried out, involving hypertensive participants for two months.
Where, as registered
No US site; Brazil (1).
RecruitingNCT07597005
Red Propolis Supplementation as a Strategy in Chronic Kidney Disease
No phase
Universidade Federal Fluminense
About 40 people
Started Sep 30, 2025
In plain words A study of propolis in people 18 to 65, run by Universidade Federal Fluminense. It plans to enroll about 40 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65. Conditions: Kidney Disease; Oxidative Stress; Chronic Kidney Disease; Inflammation.
patients with CKD stages 3-5 under conservative management
The exclusion criteria are on the listing.
What it tests, as registered
Red Propolis; Placebo Control
Registered summary
The objective of this study is to evaluate the effects of red propolis on inflammation and oxidative stress in patients with chronic kidney disease on conservative management.
Where, as registered
No US site; Brazil (1).
Not yet recruitingNCT07114926
Study on the Function of Taiwan Green Propolis in Reducing Blood Lipids and Body Fat in Sub-healthy Groups: MASLD
No phase
Kuo,HSIN-YU
About 60 people
Starts Aug 30, 2025 (estimated)
In plain words A study of propolis in people 18 to 80, run by Kuo,HSIN-YU. It plans to enroll about 60 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 80; healthy volunteers accepted. Conditions: MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease.
What it tests, as registered
Taiwanese green propolis; placebo
Registered summary
This study investigates the effectiveness of Taiwanese green propolis in reducing blood lipids and body fat in sub-healthy individuals. The study design follows a parallel, double-blind, randomized assignment approach, dividing participants into an experimental group (propolis) and a control group (placebo). Researchers explained the study plan to participants, and after obtaining signed informed consent, participants were randomly assigned using a web-based program that generated random serial numbers. The full summary is on the listing.
Where, as registered
No US site; Taiwan (1).
Not yet recruitingNCT07073092
Propolis for Management of Chemotherapy-Induced Oral Mucositis in Pediatric Patients
Phase 2
Ain Shams University
About 50 people
Starts Jul 15, 2025 (estimated)
In plain words A Phase 2 study of propolis in people 2 to 18, run by Ain Shams University. It plans to enroll about 50 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 2 to 18; healthy volunteers accepted. Conditions: Oral Mucositis Due to Chemotherapy.
Children of both genders less than 18 years receiving intensive chemotherapy.
Oncology patients receiving intensified chemotherapy at Oncology unit, Children's Hospital, Ain Shams University, Egypt, who meet the following criteria:
Taking intensified chemotherapy
A healthy oral mucosa.
The exclusion criteria are on the listing.
What it tests, as registered
propolis; chlorohexidine mouthwash and topical antifungal
Registered summary
The goal of this clinical trial is to evaluate the efficacy of propolis in the prevention of oral mucositis and reducing pain score in children undergoing chemotherapy, and assessing its impact on body mass index, pediatric quality of life and total antioxidant assay. The main question it aims to answer is: What is the effect of propolis on oral mucositis scores in children undergoing chemotherapy? Participants will: Take propolis 3 times daily for 21 days follow up weekly for 3 weeks
Where, as registered
No US site; Egypt (1).
Not yet recruitingNCT07596992
Effects of Royal Jelly and Propolis on Metabolomic Signatures, Inflammation, and Cardiovascular Risk in Patients With Coronary Artery Disease.
No phase
Universidade Federal Fluminense
About 50 people
Starts May 18, 2026 (estimated)
In plain words A study of propolis in people 18 and older, run by Universidade Federal Fluminense. It plans to enroll about 50 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Coronary Artery Disease (CAD); Oxidative Stress; Inflammation.
Both sexes
Over 18 years of age;
Diagnosed with Coronary Artery Disease: confirmed by coronary angiography, coronary computed tomography angiography, or functional testing with ischemic load);
Participants who are asymptomatic or have angina limited to functional class III will be considered;
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Propolis + Royal Jelly; Placebo
Registered summary
The aim of this project is to evaluate the effect of bioactive compound sources, propolis and royal jelly, on metabolomics, inflammation, and cardiovascular risk markers in participants with coronary artery disease. A longitudinal double-blind randomized clinical trial will be carried out, involving CAD participants for two months.
Where, as registered
No US site; Brazil (1).
Not yet recruitingNCT07578311
Effect of a Herbal Intracanal Medication On Postoperative Pain And Flare up Incidence In Non Surgical Root Canal Retreatment
No phase
Minia University
About 40 people
Starts Jul 2026 (estimated)
In plain words A study of propolis in people of any age, run by Minia University. It plans to enroll about 40 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people of any age; healthy volunteers accepted. Conditions: Postoperative Pain; Flare Up, Symptom; Flare up.
Failed previously performed endodontic treatment of single-rooted teeth.
Presence of a periapical lesion ranging from 1 mm to 2 mm in diameter.
Teeth with complete root formation.
Teeth without evidence of external or internal root resorption.
The exclusion criteria are on the listing.
What it tests, as registered
Calcium hydroxide; Propolis Extract; Green Tea Polyphenolics (EGCG)
Registered summary
The primary objective of this randomized clinical trial is to evaluate and compare the effectiveness of two natural, herbal-based intracanal medications-Propolis and Green Tea Polyphenolics (EGCG)-against the conventional Calcium Hydroxide in reducing postoperative pain and the incidence of flare-ups during non-surgical root canal retreatment. Postoperative pain is a common complication in endodontics, particularly in retreatment cases where complex bacterial environments and procedural challenges increase the risk of discomfort and acute flare-ups. The full summary is on the listing.
Where, as registered
No sites listed yet.
Not yet recruitingNCT07681310
GreenArt: Nutrikinetics and Bioavailability Studies
No phase
Fytexia
About 10 people
Starts Jun 2026 (estimated)
In plain words A study of propolis in people 25 to 69, run by Fytexia. It plans to enroll about 10 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 25 to 69; healthy volunteers accepted. Conditions: Nutrition, Healthy.
Provision of signed and dated informed consent form.
Stated willingness to comply with all study procedures and availability for the duration of the study.
Male and female with 40% min. and 60% max. of each sex.
Aged 25 to 69 years old
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
GreenArt D is a baccharis-type propolis powder extract containing phenolic compounds such as prenylated phenylpropanoids derived from hydroxycinnamic acids and flavonoids.; GreenArt 4D is a baccharis-type propolis powder extract containing phenolic compounds such as prenylated phenylpropanoids derived from hydroxycinnamic acids and flavonoids.; Placebo
Registered summary
The aim of this study is to investigate phenolic compounds from GreenArt, a baccharis-type propolis ingredient, bioavailability and nutrikinetics by measuring urinary excretion and metabolic profile over 48h by means of high-performance liquid chromatography coupled with tandem mass spectrometry (HPLC-MS/MS). The study follows a cross-over, double-blind, randomized and placebo control design on 10 healthy subjects.